SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test
At DNA Labs UAE, we offer the SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test. This test is designed to identify mutations in the SLC26A3 gene that can lead to secretory chloride diarrhea type 1, also known as congenital chloride diarrhea (CCD).
Test Components
The test includes the following components:
- SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test
Price
The cost of the test is 4400.0 AED.
Sample Condition
We accept blood or extracted DNA samples for this test. Alternatively, you can provide one drop of blood on an FTA card.
Report Delivery
Reports are typically delivered within 3 to 4 weeks.
Method
The SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test utilizes NGS (Next-Generation Sequencing) technology.
Test Type
This test falls under the category of metabolic disorders.
Doctor
The test can be ordered by a general physician.
Test Department
This test is conducted in our Genetics department.
Pre Test Information
Prior to the test, it is important to provide the clinical history of the patient who is undergoing the SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test. Additionally, a genetic counseling session is recommended to draw a pedigree chart of family members affected with Diarrhea type 1, secretory chloride, congenital.
Test Details
The SLC26A3 gene is responsible for encoding a protein called chloride transporter 3 (ClC-3), which plays a role in the movement of chloride ions across cell membranes. Mutations in the SLC26A3 gene can result in secretory chloride diarrhea type 1, also known as congenital chloride diarrhea (CCD).
CCD is a rare genetic disorder characterized by the inability of the intestines to properly absorb chloride ions. This leads to excessive chloride secretion into the intestines, causing watery diarrhea with high chloride and sodium concentrations. CCD is present from birth and can lead to severe dehydration and electrolyte imbalances if not managed properly.
The SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test utilizes NGS technology to identify mutations in the SLC26A3 gene and other genes associated with CCD. This comprehensive testing method allows for the simultaneous analysis of multiple genes, providing a thorough evaluation of the genetic causes of the disorder.
By confirming a diagnosis of CCD and identifying specific mutations in the SLC26A3 gene, NGS testing can provide crucial information for the proper management and treatment of individuals with suspected CCD. It can also assist with family planning and genetic counseling by determining the risk of passing the condition on to future children.
| Test Name | SLC26A3 Gene Diarrhea type 1 secretory chloride congenital Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Metabolic Disorders |
| Doctor | General Physician |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for SLC26A3 Gene Diarrhea type 1, secretory chloride, congenital NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with Diarrhea type 1, secretory chloride, congenital |
| Test Details |
SLC26A3 gene is responsible for encoding a protein called chloride transporter 3 (ClC-3), which is involved in the movement of chloride ions across cell membranes. Mutations in the SLC26A3 gene can lead to a condition known as secretory chloride diarrhea type 1, also known as congenital chloride diarrhea (CCD). CCD is a rare genetic disorder characterized by the inability of the intestines to properly absorb chloride ions. This leads to excessive chloride secretion into the intestines, resulting in watery diarrhea with high chloride and sodium concentrations. The condition is present from birth and can lead to severe dehydration and electrolyte imbalances if not managed properly. NGS (Next-Generation Sequencing) genetic testing is a method used to identify mutations in the SLC26A3 gene and other genes associated with CCD. This type of testing allows for the simultaneous analysis of multiple genes, providing a comprehensive evaluation of the genetic causes of the disorder. NGS testing can help confirm a diagnosis of CCD and identify specific mutations in the SLC26A3 gene that are responsible for the condition. Genetic testing for CCD can be beneficial for individuals with a suspected diagnosis, as it can provide important information for proper management and treatment. It can also help with family planning and genetic counseling by determining the risk of passing the condition on to future children. |
